Avalo Therapeutics AVTX Payments For Repurchase Of Warrants
Payments For Repurchase Of Warrants at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsForRepurchaseOfWarrants.
The official record: Avalo Therapeutics’s 10-K, filed March 23, 2026, on SEC EDGAR. View the filing →
Ask your AI about Avalo Therapeutics's payments for repurchase of warrants.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Avalo Therapeutics's payments for repurchase of warrants?
- Avalo Therapeutics (AVTX) reported payments for repurchase of warrants of $0 in Q4 2025.
- How has Avalo Therapeutics's payments for repurchase of warrants changed year-over-year?
- Avalo Therapeutics's payments for repurchase of warrants decreased by 100.0% year-over-year, from $433.5K to $0.
- What does payments for repurchase of warrants mean?
- Reflects cash outflows used to buy back or settle outstanding warrants before their expiration. Companies may choose to repurchase warrants to simplify their capital structure or mitigate future dilution risks. This metric highlights active management of equity-linked liabilities and the associated impact on cash reserves.